Document is current

Article History

Accepted: 13 April 2025

First Online: 30 May 2025

Declarations

:

: This study was funded by GSK (studies 205678, 207495, 207497, 207503, 207499, 209626, 209628). Drug linker technology was licensed from Seagen Inc.; monoclonal antibodies were produced using POTELLIGENT Technology licensed from BioWa.

: Theodoros Papathanasiou, Xi Chen, Yu Liu Ho, Herbert Struemper, Fernando Carreño, and Geraldine Ferron-Brady are employees of and hold financial equities in GSK. Josh Kaullen, Kishore Polireddy, and Adekemi Taylor are employees of Certara and provide consultancy to GSK. Josh Kaullen and Adekemi Taylor are also stockholders of Certara.

: All studies were conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. Protocols and informed consent forms were reviewed and approved by institutional review boards/independent ethics committees according to local guidelines.

: Patients in each study provided written informed consent.

: Not applicable.

: All authors were involved in manuscript writing, review, and editing and read and approved the final manuscript. Theodoros Papathanasiou, Xi Chen, Yu Liu Ho, Adekemi Taylor, Herbert Struemper, Fernando Carreño, and Geraldine Ferron-Brady contributed to study conception and design. Xi Chen, Yu Liu Ho, Herbert Struemper, Fernando Carreño, and Geraldine Ferron-Brady were responsible for data acquisition. Josh Kaullen, Kishore Polireddy, and Adekemi Taylor analyzed the data. All authors were involved in data interpretation.

: GSK makes available anonymized individual participant data and associated documents from interventional clinical studies that evaluate medicines, upon approval of proposals submitted to .

: Available upon reasonable request.